Company / Shareholders' Equity
ArriVent BioPharma, Inc. Shareholders' Equity History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$257.7M
FY2024
5-year range
-$153.2M / $257.7M
FY2023-FY2024
Trend
+268.2%
vs FY2023
Sector context
#143 of 213
Health Care
What the data says
At $258M, ArriVent BioPharma, Inc.'s shareholders' equity ranks #143 of 213 in the Health Care sector.
Based on SEC 10-K filings.
$258M in FY2024.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#143 of 213 in Health CareTop 67% of 213This company $257.7M Sector average $2.5B
▼
-89.9% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity increased 268.2% year-over-year.
- Ranks #143 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $257.7M | +268.2% |
| FY2023 | -$153.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026